文献速递妇科

EP-100联合紫杉醇对比单用紫杉醇治疗难治/复发性卵巢癌的II期随机试验

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-11-23

这项开放标签随机II期研究评估了EP-100联合每周紫杉醇在LHRH受体阳性复发性卵巢癌患者中的安全性和临床活性。非计划分析观察到靶向肝病灶患者联合组ORR更高(69% vs 16%)。

要点

  • 联合组与单药组ORR相似(35% vs 33%)。
  • 肝转移亚组联合组ORR更高(69% vs 16%)。
  • 联合组3-4级治疗相关不良事件发生率与单药组相近(48% vs 43%)。

核心结论

  • EP-100联合紫杉醇的ORR与紫杉醇单药相似,但肝转移亚组可能从联合治疗中获益。
  • 联合EP-100未明显增加紫杉醇的不良事件,耐受性良好。

研究设计与样本

  • 多中心开放标签随机II期试验,纳入LHRH受体阳性的复发性卵巢癌患者。
  • 联合组:每周紫杉醇80 mg/m2静脉注射+每周两次EP-100 30 mg/m2静脉注射;单药组:每周紫杉醇80 mg/m2静脉注射。
  • 主要终点为总缓解率(ORR)。

主要发现

  • 联合组ORR为35%(95%CI 16%-57%),紫杉醇单药组为33%(95%CI 15%-57%)。
  • 非计划分析显示,靶向肝病灶患者联合组ORR为69%,单药组为16%。
  • 治疗相关3-4级不良事件发生率联合组48%,单药组43%。

关键数值与推荐

  • ORR:联合组35%(95%CI 16%-57%),单药组33%(95%CI 15%-57%)。
  • 肝病灶亚组ORR:联合组69%,单药组16%。
  • 3-4级治疗相关不良事件:联合组48%,单药组43%。
  • EP-100剂量:30 mg/m2每周两次静脉注射;紫杉醇剂量:80 mg/m2每周静脉注射。

临床怎么用

  • 对于LHRH受体阳性的复发性卵巢癌患者,EP-100联合紫杉醇的总体疗效与紫杉醇单药相似。
  • 伴有肝转移的患者可能从EP-100联合紫杉醇治疗中获得更高的缓解率,但需进一步验证。
  • 联合方案未显著增加3-4级不良事件,耐受性良好。

局限性

  • 肝病灶亚组分析为非计划分析,结果需谨慎解读。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This randomized open-label phase II study evaluated the safety and clinical activity of EP-100 plus weekly paclitaxel in patients with recurrent ovarian cancer expressing positive LHRH receptor. METHODS: In a limited "run-in" dose escalation phase for EP-100, six patients were treated with ascending dose levels (13 mg/m2, 20 mg/m2, 30 mg/m2). In the randomized phase, patients received weekly paclitaxel (80 mg/m2 intravenously) plus twice weekly EP-100 (30 mg/m2 intravenously; combination arm) or weekly paclitaxel alone (80 mg/m2 intravenously; paclitaxel arm). The primary study endpoint was overall response rate (ORR). RESULTS: Forty-four patients were then randomized to either the experimental combination arm (n = 23) or the standard of care paclitaxel monotherapy arm (n = 21). The ORR was 35% (95%CI 16%-57%) for the combination arm and 33% (95% CI 15%-57%) for the paclitaxel arm. An interesting observation from an unplanned analysis was that a subset of patients with target liver lesions showed a greater overall response rate to the combination (69%) compared to paclitaxel alone (16%). The frequency of treatment-related grade 3-4 adverse events was similar between treatment arms: 48% vs 43% for the combination and paclitaxel arms, respectively. CONCLUSIONS: ORR in the EP-100 combination arm was similar to that in the group treated with paclitaxel alone; however, a subset of patients with liver metastases appeared to benefit from the combination. The addition of EP-100 did not appear to augment the adverse event profile of paclitaxel and was well tolerated.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chelariu-Raicu A, Nick A, Urban R, et al. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Gynecol Oncol. 2020. PMID: 33243443. doi:10.1016/j.ygyno.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。